3rd Heart Failure Drug Discovery & Development Summit – What’s it About?

The 3rd Heart Failure Drug Discovery & Development Summit returns to tackle key challenges facing preclinical heart failure drug development by uniting 50+ biopharma to delve into targeting, stratifying and treating cardiomyopathies with greater precision.

Key Agenda Highlights

Elevate your understanding of precision approaches to heart failure with Bayer & Tenaya

Unearth developments in accelerating the translatability for heart failure disease modelling with Pfizer & Novo Nordisk

Stay ahead of the curve on developments in the intersection of aging biology and heart failure with Regeneron

Delve into novel biology from non-coding RNAs to gene therapy and small molecules with LEXEO, Cytokinetics & Cardior

Increase your understanding on optimal stratification of heart failure with Novartis

Who Will You Meet?

This summit stands as the hub of knowledge, showcasing the latest in developments in the preclinical heart failure drug development. Together with 50+ experts, immerse yourself and your team in cutting-edge cardiac drug development from discovery to target validation.

image (3)

What Your Peers Have to Say

 ‘’Exciting agenda of high relevance to precision cardiology’’

Senior Director, Bayer

Who's Speaking?

41700 - Homepage slide (4)